A California-based pharmaceutical company, Ionis Pharmaceuticals announced that Damien McDevitt will be added in the Ionis family as the chief business officer. In his role, McDevitt will serve as a member of Ionis’ executive leadership team. Alongside, he will provide strategic guidance and lead Ionis’ corporate development activities such as business development, patient advocacy, competitive intelligence and many more.

Chief operating officer and senior vice president, Brett P. Monia said, “Damien is a highly experienced and accomplished leader in the pharmaceutical industry. His strong background in both science and business enable him to contribute broadly to all areas of the company.” Further, he stated that his leadership will be invaluable. Brett said, “I am excited about the wealth of experience that Damien brings to Ionis, which will be instrumental as we become a multi-product, sustainably profitable company.”

Before joining Ionis, Dr. McDevitt he served as senior vice president, corporate development at ACADIA Pharmaceuticals. Prior to ACADIA, Mr. McDevitt was at GSK for more than two decades. The sources stated that he served various roles with increasing responsibility including vice president, head of business development for R&D Extended Therapy Areas.

Dr. McDevitt said, “I am joining Ionis at an exciting time. Just this year, Ionis has seen its first commercial drug for a neurological disease, SPINRAZA, reach blockbuster status. Ionis is continuing to build on this momentum with the planned launches of two new drugs this year and readouts from multiple important clinical studies.”